Daniel Molnar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Molnar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Henle2 shared publications
Kai Berkenfeld
2 shared publications- Lukas Muehlfeld
Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, Pharmaceutical Development Biologicals, 88397 Biberach, Germany
2 shared publications - Patrick Garidel
Boehringer Ingelheim Pharma GmbH & Co KG, Innovation Unit, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
2 shared publications - Alf Lamprecht
Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany
1 shared publication Annika Michel
Boehringer Ingelheim Pharma GmbH & Co. KG, Formulation and Process Development Biologicals Late Stage, 88397 Biberach, Germany; Institute of Applied Biotechnology, Faculty for Biotechnology, Biberach University of Applied Sciences, 88400 Biberach, Germany; Faculty for Natural Sciences, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 9 August 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 178, 117-130
A Novel MATLAB®-Algorithm-Based Video Analysis to Quantitatively Determine Solution Creeping in Intact Pharmaceutical Glass Vials
- 9 August 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 178, 117-130
Open AccessA Novel MATLAB®-Algorithm-Based Video Analysis to Quantitatively Determine Solution Creeping in Intact Pharmaceutical Glass Vials
- Open Access
- 2 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 352
Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Although a deeper understanding of the underlying mechanisms of IBD has led to new therapeutic approaches, treatment options are still limited. Severe adverse events in conventional drug therapy and poor drug targeting are the main cause of early therapy failure. Nanoparticle-based targeting approaches can selectively deliver drugs to the site of inflammation and reduce the risk of side effects by decreasing systemic availability. Here, we developed a nanoparticulate platform for the delivery of the anti-TNF-α antibody adalimumab (ADA) by covalent crosslinking to the particle surface. ADA binding to nanoparticles improved the stability of ADA against proteolytic degradation in vitro and led to a significantly better therapeutic outcome in a murine colitis model. Moreover, immobilization of ADA reduced systemic exposure, which can lead to enhanced therapeutic safety. Thus, nanoparticle protein decoration constitutes a platform through which epithelial delivery of any biological of interest to the inflamed gut and hence a local treatment can be achieved.
- 2 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 352
Open AccessAdalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Although a deeper understanding of the underlying mechanisms of IBD has led to new therapeutic approaches, treatment options are still limited. Severe adverse events in conventional drug therapy and poor drug targeting are the main cause of early therapy failure. Nanoparticle-based targeting approaches can selectively deliver drugs to the site of inflammation and reduce the risk of side effects by decreasing systemic availability. Here, we developed a nanoparticulate platform for the delivery of the anti-TNF-α antibody adalimumab (ADA) by covalent crosslinking to the particle surface. ADA binding to nanoparticles improved the stability of ADA against proteolytic degradation in vitro and led to a significantly better therapeutic outcome in a murine colitis model. Moreover, immobilization of ADA reduced systemic exposure, which can lead to enhanced therapeutic safety. Thus, nanoparticle protein decoration constitutes a platform through which epithelial delivery of any biological of interest to the inflamed gut and hence a local treatment can be achieved.